GLP1R and type 2 diabetes mellitus: Kristensen et al. [99] reported a reduction in renal composite outcomes (new-onset macroalbuminuria, decline in eGFR, ESKD, or death) by 17% in individuals with T2D on GLP-1 receptor agonists.